CR20190329A - MODULADORES DEL FACTOR DEL COMPLEMENTO B (Divisional 2016-0170) - Google Patents
MODULADORES DEL FACTOR DEL COMPLEMENTO B (Divisional 2016-0170)Info
- Publication number
- CR20190329A CR20190329A CR20190329A CR20190329A CR20190329A CR 20190329 A CR20190329 A CR 20190329A CR 20190329 A CR20190329 A CR 20190329A CR 20190329 A CR20190329 A CR 20190329A CR 20190329 A CR20190329 A CR 20190329A
- Authority
- CR
- Costa Rica
- Prior art keywords
- complement factor
- complement
- modulators
- cfb
- dysregulation
- Prior art date
Links
- 230000000295 complement effect Effects 0.000 title abstract 2
- 102000003712 Complement factor B Human genes 0.000 abstract 4
- 108090000056 Complement factor B Proteins 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 230000008482 dysregulation Effects 0.000 abstract 2
- 239000003112 inhibitor Substances 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 230000024203 complement activation Effects 0.000 abstract 1
- 230000037361 pathway Effects 0.000 abstract 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Las presentes modalidades proporcionan métodos, compuestos y composiciones para tratar, prevenir o mejorar una enfermedad asociada con la desregulación de la vía alternativa 5 de complemento mediante la administración de un inhibidor específico del factor del complemento B (CFB) a un sujeto.The present embodiments provide methods, compounds, and compositions for treating, preventing, or ameliorating a disease associated with dysregulation of the complement alternative pathway by administering a Complement Factor B (CFB) specific inhibitor to a subject.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2014/055458 WO2015038939A2 (en) | 2013-09-13 | 2014-09-12 | Modulators of complement factor b |
| US201661877624P | 2016-09-13 | 2016-09-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20190329A true CR20190329A (es) | 2019-09-13 |
Family
ID=68343558
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20190329A CR20190329A (es) | 2014-09-12 | 2014-09-12 | MODULADORES DEL FACTOR DEL COMPLEMENTO B (Divisional 2016-0170) |
Country Status (1)
| Country | Link |
|---|---|
| CR (1) | CR20190329A (es) |
-
2014
- 2014-09-12 CR CR20190329A patent/CR20190329A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2018001996A1 (es) | Composiciones y métodos para modular la expresión del factor b del complemento (divisional de solicitud 2764-16) | |
| CR20160170A (es) | Moduladores del factor del complemento b | |
| DOP2020000102A (es) | Compuestos útiles para inhibir a cdk7 | |
| CL2020000215A1 (es) | Compuestos y composiciones para tratar afecciones asociadas con la actividad nlrp. | |
| CO2017013065A2 (es) | Moduladores de diaciglicerol aciltransferasa 2 (dgat2) | |
| BR112018004620A2 (pt) | moduladores da expressão de kras | |
| JOP20210050A1 (ar) | معدلات تعبير pnpla3 | |
| ECSP19072372A (es) | Moduladores de la expresión de pcsk9 | |
| ECSP21053104A (es) | Moduladores de la expresión de hsd17b13 | |
| CL2020000586A1 (es) | Moduladores de la expresión de enac. | |
| BR112016015578A2 (pt) | Inibidores de 17beta-hidroxiesteroide desidrogenases tipo 1 e tipo 2 | |
| MX2018006631A (es) | Compuesto para uso en la prevencion y tratamiento de enfermedades neurodegenerativas. | |
| AR106415A1 (es) | Composición farmacéutica para el tratamiento del dolor | |
| CR20190329A (es) | MODULADORES DEL FACTOR DEL COMPLEMENTO B (Divisional 2016-0170) | |
| BR112017008659A2 (pt) | ?métodos e compostos de agonista de gip? |